Particulate vector systems for the presentation of immunogenic epitopes provide an alternate and powerful approach for the delivery of immunogens of interest. In this article, we have exploited a viral protein of unknown function, bluetongue virus (BTV) nonstructural protein NS1, which forms distinct tubular aggregates in infected cells, as an immunogen delivery system. Tubules are helical assemblies of NS1 protein that present the C-terminus of the protein to the outer edge effectively displaying appended residues in a regular and repeating array akin to the coat of a filamentous phage. To assess the breadth of response induced following tubule-based immunization, two different immunodominant foreign peptides were inserted at the C-terminus of NS1 and chimeric tubules generated following expression in the baculovirus expression system. Both constructs, one carrying a peptide of foot and mouth disease virus (FMDV) (aa 135-144 of VP1) and the other, a peptide of influenza A virus (aa 186-205 of HA), effectively assembled into tubules and were easily purified. Subsequently, using in vitro assay systems, we demonstrated that each purified chimeric particle was capable of eliciting strong immune responses. Further, NS1-FMDV chimeric tubules could induce a potent immune response that could protect against disease. © 2002 Elsevier Science (USA) 
INTRODUCTION
Attempts to enhance the immunogenicity of antigens for use as vaccines have led to the development of a number of antigen presentation systems. Various vaccines based on the major immunodominant epitopes of a virus have been developed that alleviate problems associated with "whole" virus vaccines (Nardelli and Tam, 1995; Ben-Yedidia and Arnon, 1997) . However, protection with such systems often requires multiple rounds of immunization and is generally strain specific (Brown et al., 1992) . Enhancement of the immune response has been shown to occur when immunodominant epitopes are presented to the immune system in a multiple array displaying on the surface of a complex carrier such as on the hepatitis B virion (Clarke et al., 1987) . However, the molar proportion of the immune active component to the carrier is often very low and the complexity of production also limits useful application. Moreover, similar to the hepatitis B virus, many virus capsid-based delivery systems have limitations in their capacity to accommodate foreign sequences due to packaging constraints (Adams et al., 1987; Clarke et al., 1987; Evans et al., 1989; French and Roy, 1990; Belyaev and Roy, 1993; Griffiths et al., 1993; LeBlois and Roy, 1993; Miyamura et al., 1994; Adler et al., 1998) .
The nonstructural protein NS1 of bluetongue virus (BTV) multimerizes into stable tubular structures in infected cells, the role of which is unclear. The tubules are approximately 52.3 nm in diameter and up to 1000 nm in length and are composed of helically coiled ribbons of NS1 "dimers," with 21 or 22 dimers per turn (Hewat et al., 1992) .
Previously, we localized a major antigenic site at the C-terminus of the NS1 protein of BTV (Monastyrskaya et al., 1995) and, as this site is exposed on the surface of the tubule suggested, it could potentially incorporate considerably large foreign sequences for immune presentation without perturbing the helical structures. Indeed, when C-terminus was manipulated to insert extra sequences, it was possible to generate chimeric tubules carrying large foreign polypeptides (Mikholov et al., 1996) .
In this article we wanted to determine whether such particles could elicit immune responses. To this end we have used two established immunogenic epitopes, one derived from VP1, the antigenic protein of foot and mouth disease virus (FMDV), and the other, from the hemagglutinin (HA) protein of influenza A virus, to generate chimeric NS1 tubules. The rationale for selection of these two epitopes is that while the FMDV VP1 peptide (aa 135-144) has been documented to elicit a particular humoral response (Zamorano et al., 1994) , the HA peptide (aa 186-205) has been reported to elicit cell-medi-ated immunity (Fox et al., 1989) . Chimeric tubules were expressed by recombinant baculoviruses; purified and appropriate in vitro and in vivo immune responses against each peptide were assessed. In addition, following immunization, the protective efficacy of NS1-FMDV chimera was determined by a virulent virus challenge in mouse model system. Our data showed that purified chimeric tubules induce both humoral and cell-mediated responses and suggest that tubule-based vaccines offer significant advantage for the induction of broad ranging immune responses with the potential for protection.
RESULTS

Recombinant baculovirus-derived chimeric NS1 proteins generate tubular structures in insect cells
Two different chimeric constructs were designed, one to assess the CD4 ϩ Th response and the other to assess protective humoral immune response. Therefore, two recombinant baculovirus transfer vectors, one containing the VP1 sequence (aa 135-144) of FMDV and the other containing the influenza A HA sequence (aa 186-205) downstream of NS1 gene were constructed and recombinant baculoviruses were generated as described under Materials and Methods. The level of chimeric protein expression of each protein was monitored by SDS-PAGE analysis from insect cells infected with each recombinant virus. As shown in Fig. 1A both recombinant viruses expressed high level of chimeric NS1 protein (lanes c and d) and that the level of expression of each chimeric protein was as high as the wild-type NS1 expression (lane e). The origin and authenticity of each protein band was confirmed by Western blot analysis using an anti-NS1 mouse serum. While both chimeric bands and the wild-type NS1 band were detected by anti-NS1 anti-serum ( Fig. 1B, lanes b and c) , only the chimeric NS1 tubules were reacted with antiserum specific for FMDV peptide (Fig. 1C, lane a) , or anti-HA antibody (data not shown).
Formation of tubular structure by chimeric NS1 protein
As immune stimulation by NS1 fusion proteins requires the formation of chimeric NS1 tubules, each of the recombinant virus-infected insect cells were examined for their capabilities to form NS1-like tubules by electron microscopy. Sections of infected cells showed the accumulation of tubules as seen for previously reported recombinant NS1 tubules (Urakawa and Roy, 1988) , demonstrating that the insertion of either FMDV VP1 peptide or the HA peptide does not perturb the tubular morphology (data not shown). The tubule-forming capability of the fusion protein was further characterized by biochemical methods. Since NS1 tubules could be readily isolated by sucrose gradient centrifugation (Urakawa and Roy, 1988) , insect cells infected with the recombinant baculoviruses were lysed and the cytoplasmic extracts sedimented through a 10-40% sucrose gradient. To provide a positive control, NS1 tubules representing the wild-type protein were similarly processed. Each sucrose gradient was fractionated and aliquots from each fraction were analyzed by SDS-PAGE. Both wild-type NS1 and the chimeric NS1 products detected in broad bands were present predominantly in fractions 3 to 7 of each gradient ( Fig. 2A ). When peak fractions of each sample were analyzed by SDS-PAGE, only a single protein band was present in each case, confirming that tubules were highly purified ( Fig. 2B ). Further, when fractions of each gradient containing NS1 tubules were ex- amined by electron microscopy, both types of chimeric particles exhibited similar morphology and were identical to those made by wild-type NS1 and morphologically identical to that found in infected cells (Fig. 3) . These data indicate no loss of the tubule structure upon isolation, an important factor for scale up and use as an immunogen delivery system.
Chimeric tubules can stimulate CD4 ϩ T cell proliferation
The T cell responses to an immunogen can be defined with synthetic peptides specific for each mouse haplotype and through isolation of responsive T cells as CD4 ϩ T cell clones for in vitro study of their specificity. In addition, in vitro binding of synthetic peptides to MHC class II antigens correlates with in vivo defined T cell recognition specificity (Benjamin et al., 1984) . The majority of HA-specific CD4 ϩ T cell clones derived from influenza X31 virus (H3N2 subtype) infected C57BL/10 (H-2 b ) mice have been shown to recognize a unique HA epitope that encompasses amino acid residues 186-205 (Barnett et al., 1989a,b) . Such HA-specific T cell clones can be used to assess the immune response to the chimeric NS1-HA construct in an in vitro T cell proliferation assay. T cell lines were established from the spleens of individual BALB/c mice primed by intranasal infection with X31 virus (5HAU) and HA-specific T cell clones were isolated from these B10 (H-2 b ) mice and maintained as described previously (Barnett et al., 1989a,b) .
To assess if the NS1-HA chimeric tubules could induce immune responses, we used the HA-specific T cell clones for a comparison of their proliferative activity with wild-type tubules and HA peptide. When proliferative responses of isolated clones to the NS1-chimera were compared with the control peptide (HA aa 186-205) at different doses, the chimera significantly stimulated the proliferation of CD4 ϩ T cell clones (see Fig. 4 ). The data indicated that the peptide presented by the chimeric NS1 tubule was recognized by CD4 ϩ T cell clones from MHC matched donors. No such response was obtained with purified wild-type tubules in a parallel experiment, indicating that the proliferative response obtained with the chimeric construct was specific (see Fig. 4 ). Interestingly, the construct could also stimulate MHC-mismatched CD4 ϩ T cell clones, albeit to a lesser extent than the MHC matched samples, but to a significantly higher level than peptide alone (see Fig. 4 ). These data show that influenza A HA (186-205) epitope is recognized efficiently in a dose-dependent manner by at least two MHC haplotypes (H-2 b , Fig. 4 , left and H-2 d , Fig. 4 , right) when displayed on the surface of the NS1 tubules.
Stimulation of IFN-␥ production by chimeric tubules
The immune response to chimeric tubules was confirmed by an alternative assay for T cell activation marked by the release of IFN-␥. Chimeric tubules stimulated the release of IFN-␥ from a CD4 ϩ clone derived from C57BL/10 (H-2 b ) mice as did free HA (186-205) peptide (Fig. 5, top) , but not the peptides HA1 48-67 and HA1 68-83, as reported previously (data not shown; Barnett et al., 1989a) . Recombinant tubules were between two to four times better than free peptide on a weight-to-weight basis in stimulating IFN release ( Fig. 5 , based on 2.5 and 5 g samples). Taking into account the relative molecular weight of the NS1 chimera (64 kDa) and peptide (2 kDa), stimulation by NS1 peptide was ϳ100-fold better when calculated on a mole equivalence basis. Some activation of MHC mismatched (H-2d) clones was also apparent (Fig. 5, bottom) , although the release of IFN-␥ was at a much lower level. As expected, no response was obtained when wild-type recombinant tubules were used as control (Fig. 5, top and bottom) . Taken together with the proliferation data and taking into account the difference in molecular weight of the free peptide and NS1 chimera, it is clear that the chimeric tubule stimulated CD4 ϩ T cell clones more efficiently on a mole-to-mole basis if the epitope was presented as part of a multivalent chimeric tubules than as peptide alone.
FIG. 4. Proliferative responses of T cell clones to chimeric tubules. Proliferation assays for T cell clones derived from each of two strains of mice (BALB/c, right and BH10, left) stimulated by either free peptide (diamonds) or NS1-peptide fusion proteins (squares) or wild-type (wt) NS1 tubules (circle). Assays were performed in triplicate and the results represent the arithmetic mean of [ 3 H]thymidine incorporation for the cultures. Data shown are the results of three different experiments, each of which varied by no more than 10%.
Chimeric tubules elicit protective immune response in mice
The region between residues aa 135 and 144 of VP1 contains natural immunodominant B and T cell epitopes. It has been reported previously that three different animal species, cattle (Zamorano et al., 1994) , mice (Zamorano et al., 1995) , and guinea pig , strongly recognized this region. However, immunization of mice or cattle with this peptide alone completely failed to elicit any immune response. Only when coupled to bovine serum albumin (BSA) was the peptide able to elicit a FMDV-specific response. The same was true when p135-144 peptide was used as a dimer (Zamorano et al., 1995 . Based on this observation, we explored whether NS1 tubules carrying a single-copy peptide p135-144 could elicit an appropriate immune re-sponse against the VP1 peptide or more importantly the virus, and furthermore, whether such a response in turn had any protective efficacy against virulent virus challenge.
A group of seven BALB/c mice was immunized and boosted twice with a 50 g/dose of either chimeric or wild-type tubules intraperitoneally. Ten days after the last booster, animals were bled and the sera analyzed for the presence of anti-FMDV antibodies. The experiment was independently performed four times. Antibodies raised in immunized mice with chimeric tubules showed significant antibody response against VP1 as demonstrated by their reactivity to aa 135-160 peptide in ELISA (see Fig.  6 ). Equally strong antibody responses were obtained when intact FMDV particles were used as antigen in ELISA. In contrast, sera from mice immunized with wild-FIG. 5. Stimulation of IFN-␥ production by chimeric tubules. Interferon gamma, measured by ELISA assay, present in the culture supernatant from T cell clones derived from BALB/c and BH10 mice upon stimulation with free peptide, NS1-fusion protein, wild-type (wt) NS1 tubules. Values are the mean of three independent experiments in each of which in vitro stimulation was carried out in triplicate. Note the figures are not corrected for molar equivalence (NS1-peptide fusion proteins being ϳ30ϫ the molecular weight of free peptide). type tubules showed no reactivity against either the VP1 or the intact virions, indicating that the immune response induced by the NS1.FMDV tubules was specific.
To assess whether the immunity developed in each animal was sufficient to confer protection against virus infection, each immunized mouse was challenged with 10 4 lethal doses (SMLD 50 ) of FMDV O1 Campos intraperitoneally . It has been shown previously that intraperitoneal inoculation of 10 4 SMLD 50 in most mouse strains replicates intensively in its major target organ, the pancreas, within 36-48 h and by 48-72 h has accumulated a high titer viremia (5 to 7 logs of virus). However, the presence of a protective immune response aborts virus replication in the pancreas and prevents the appearance of viremia. Thus, protected mice do not develop viremia at any time postinfection, while nonimmune mice suffer a pancreatic infection and viremia. Viremia is easily detected by inoculating suckling mice, perhaps the most sensitive system for detecting infectious FMDV other than the intradermal inoculation in cattle. The protocol for detecting the presence of viremia in adult mice has been developed to form a robust assay (Zamorano et al., 1995; Wigdorovitz et al., 1999; Dus Santos et al., 2000) . Therefore, protection afforded by the chimeras was determined by the absence of viremia in the blood samples of the challenged mice at 36 h postinfection. Viremia was assessed by intramuscular (im) inoculation of 50 l/mice of a 1/100 dilution of peripheral blood samples of the challenged animals in 5to 6-day-old newborn BALB/c mice and the presence of viremia was indicated by death of the animal. When the peritoneal blood samples of the challenged mice were tested for viremia in a group of newborn mice (Zamorano et al., 1995) , 60% of the mice survived, indicating that the inoculated blood samples lacked the presence of FMDV. Thus, the surviving animals receiving the chimeric tubules had generated a sufficient immune response that protected them against the FMDV challenges. In contrast, the mice that were immunized with wild-type NS1 tubule preparation were infected with FMDV after the challenge, as the newborn mice died when inoculated with the blood samples containing the virus. The animal experiments were repeated four times to ensure the specificity of the protective response of the chimeric tubules.
DISCUSSION
Efficient presentation of an immunogenic epitope by polyvalent particulate structure has evoked considerable interest in recent years. The epitopes of interest in these cases are linked to a carrier protein, which can assemble into a predictable multimeric structure and present the carried foreign antigenic sequence to the immune system. Examples of molecules that have been used for this approach include, among others, hepatitis B surface antigen (HbsAg) (Delpeyroux et al., 1986) yeast Ty-like particles (Adams et al., 1987) , poliovirus (Evans et al., 1989) , hybrid human immunodeficiency virus Gag particles (Griffiths et al., 1993) , and parvovirus-like particles (Miyamura et al., 1994) . Similarly we have demonstrated the potential of virus-like particles based on icosahedral BTV core structure for the delivery of foreign epitopes (French and Roy, 1990; Belyaev and Roy, 1993; LeBlois and Roy, 1993; Adler et al., 1998) . One of the limitations of BTV particles and other icosahedral particle-based vectors is their inability to accommodate larger sequences, which perturb the assembly of the capsid structure. In contrast, BTV-TUBs for their characteristic helical configuration can accommodate larger sequences, even a complete antigen such as green fluorescent protein (GFP) (Ghosh et al., 2002a) and are therefore likely to carry and deliver conformational epitopes. Thus, these particulate structures made by NS1 have important implications for novel vaccine design. An additional advantage of these tubules is that the level of expression of recombinant NS1 in infected Sf cells is extremely high (300 mg/L culture), which is highly desirable for development of candidate vaccine (Urakawa and Roy, 1988 ). In addition, tubules are relatively easy to purify and, due to their size, mice immunized with these tubules in the absence of adjuvants generated a high titer of antibody comparable to those obtained using standard adjuvant protocols (M. K. Ghosh, Z. Moldeavenu, and P. Roy, unpublished observation).
FMDV is the causative agent of a very significant economic disease affecting meat and milk-producing domestic animals (Brown et al., 1992) . The structural protein VP1 of FMDV carries critical epitopes and expression of the immunogenic areas of VP1 in heterolo- Approximately 10 g of NS1-VP1 tubules were used to immunize each of a group of seven BALB/c mice. Following two boosts at two-week intervals, the mice were bled and the presence of antibodies to FMDV was assessed by an ELISA using FMDV virions or VP1 peptide as the test antigen. The response was compared to the preimmune serum from each mouse. gous systems generated experimental immunogens which could protect experimental and natural hosts (Kleid et al., 1981; DiMarchi et al., 1988; Morgan and Moore, 1989; Zamorano et al., 1998) . The VP1 sequence that we have used to generate chimeric tubules had previously been shown to constitute the shortest amino acid sequence of VP1 that had the ability to induce a protective anti-FMDV immune response (Carrillo et al., 1998; Zamorano et al., 1994 Zamorano et al., , 1998 . In these reports, a decamer (aa 135-144 epitope) of VP1, used as a synthetic peptide, elicited a protective neutralizing antibody response only when presented as a dimer. In the NS1.VP1 construct designed here, the aa 135-144 epitope is expressed as a single copy and as a Cterminal fusion protein of BTV NS1 formed tubules. These tubules were able to induce a specific anti-FMDV antibody response, which protected 60% of the immunized mice. Although the protective antibody response was relatively weak, it is the first evidence that demonstrated that a single-copy FMDV VP1 (aa 135-144) epitope, expressed as a fusion protein, could protect immunized mice against a virulent FMDV challenge. It is therefore quite conceivable that an improved design of an NS1 construct(s) that includes the adjacent flanking amino acid residues of the aa 135-144 region of VP1 and/or in presence of appropriate adjuvant may enhance the immune response. It is highly likely that the immunogenicity conferred by the chimeric tubules is probably due to the polyvalent nature of the antigen that may be important in cross-activation of immune cells.
The CD4 ϩ T cells are primarily helper T cells providing help both to B cells for antibody production and to class I restricted CD8 ϩ CTLs for their proliferation. The important role of CD4 ϩ T cells in immunity to influenza virus infection is well documented. CD4-deficient mice have been shown to develop impaired immunity to influenza virus (Nguyen et al., 2001) . It has also been noted, however, that CD4 ϩ T cells alone are unable to clear virus and to promote recovery from primary infection (Mozdzanowska et al., 1997; Topham and Doherty, 1998; Doherty et al., 1997) and have shown that during influenza virus infection CD4 ϩ T cells are important for providing help for B cells and antibody responses. The importance of B cells in generating heterosubtypic immunity to influenza A virus has also been documented recently (Nguyen et al., 2001) . It is also interesting to note that the helper T cells specific for M or NP antigens can provide help to B cells secreting HA antibody, and in the same manner, can augment the antibody response to protective antigens. The data that we have presented here clearly showed the chimeric NS1 tubules containing the appropriate epitope could indeed induce HA peptide specific CD4 ϩ T helper cell response of influenza A virus. Evidently chimeric tubules which include both B cell epitopes along with CD4 ϩ Th epitope would enhance strong influenza A virus humoral responses. In addition, inclusion of CTL epitopes to generate antiinfluenza cytotoxic responses may then complement such attempts. Indeed we have already shown that chimeric NS1 tubules can induce protective lymphocytic choriomeningitis virus (LCMV) specific class I restricted CD8 ϩ CTL response (Ghosh et al., 2002a) . To rationalize the hypothesis that more than one epitope can be used to generate chimeric tubules which will in turn induce immune responses against each type of epitopes, we have recently generated tubules containing two HLA-A2-restricted human melanoma epitopes in tandem. We have obtained evidence that such chimeric tubules were capable of inducing CTL responses against both epitopes simultaneously in vivo in HLA-A2 transgenic mice (Ghosh et al., 2002b) .
It seems quite reasonable therefore to hypothesize that, based on our accumulated data, BTV-derived chimeric tubular structures carrying broad spectrum multiple immunogenic epitopes would be highly effective against human pathogens which require both cellular and humoral responses to overcome infection.
MATERIALS AND METHODS
Viruses and cells
Spodoptera frugiperda cells were grown in suspension or monolayer cultures at 28°C in SF-900 II serumfree medium (Gibco-BRL). Derivatives of Autographica californica nuclear polyhedrosis virus (AcNPV) containing the wild-type BTV-10 NS1 gene (Ac10BTV6) and chimeric NS1 mutant were plaque purified and propagated as described previously (Brown and Faulkner, 1977) .
Mice
All animal experiments were carried out in 60-to 90-day-old male BALB/c (H-2 d/d ) mice bred in our own colony. Detection of viremia in challenged animals was performed in 5-to 6-day-old BALB/c mice litters.
Cell lines and clones
The generation of the HA-specific, CD4 ϩ T cell clones used in this study has been described elsewhere (Barnett et al., 1989b) . Briefly, T cell clones were established by limiting dilution from lines from the spleens of individual BALB/c donors primed by intranasal infection with X31 virus. T cell clones were maintained by restimulation with X31 virus (100 HAU/mL) and irradiated (3000 rad) syngeneic spleen cells (2 ϫ 10 6 /mL) as feeder cells every 10-12 days, with the addition of interleukin-2 (IL-2)-containing supernatant (prepared from concanavalin A stimulated rat spleen cells) and feeder cells, 3 days after antigen.
Chimeric mutation of the BTV-10 NS1 gene and construction of recombinant transfer vector Oligonucleotide 5Ј-CT AGT AGC TAC AGC AGA AAT GCT GTG CCC AAC GTG-3Ј and its complementary were designed to encode FMDV O1 Campos B-T cell epitope (residues 135-144 of the G-H loop of VP1 protein) . Similarly, oligonucleotide 5Ј-CT AGT AGC ACG AAC CAA GAA CAA ACC AGC CTG TAT GTT CAA GCA TCA GGG AGA GTC ACA GTC TCT-3Ј and its complementary were designed to encode the influenza A HA T helper cell epitope of residues HA (186-205) (Barnett et al., 1989a,b) . A 5Ј overhang CT AGT was designed for forward sense and a 3Ј A for the reverse-sense oligonucleotide, respectively, for insertion into SpeI and SmaI cut pAcYM1NS1SpSm transfer vector. The oligonucleotides were obtained from Amitof Biotech (Boston, MA), phosphorylated with T4 polynucleotide kinase, and annealed at 55°C for 3 min. The annealed oligonucleotides were then ligated into SpeI-and SmaI-digested pAcYM1NS1SpSm [which contains the BTV-10 NS1 gene engineered at the carboxyterminus to incorporate SpeI and SmaI sites between the last amino acid Y (552) and the stop codon], to generate the recombinant transfer vectors pNS1SpSm. FMDV.VP1 (135-144) and pNS1SpSm.Flu HA (186-205), respectively. The sequence of the inserted oligonucleotides was then confirmed by the dideoxynucleotide technique (Sanger et al., 1977) with incorporation of [ 35 S]dATP, using a sequenase version 2.0 DNA sequencing kit (U.S. Biochemical). The forward primer (HL3) is some 96 nucleotides upstream of NS1 stop codon, while the reverse primer (Bac2) corresponds to a region of the AcNPV genome that is some 60 nucleotides downstream of the NS1 insertion site and represents the sequence in the opposing DNA strand.
Isolation of recombinant baculoviruses
The lipofectin technique (Felgner et al., 1987) was used to cotransfect monolayers of Sf-9 cells with the recombinant transfer vector and Bsu36I triple-cut AcNPV DNA (Kitts and Possee, 1993) . Recombinant baculoviruses were selected on the basis of their lacZ-negative phenotypes, plaque purified, and propagated as described elsewhere (King and Possee, 1992) . From pNS1SpSm.FMDV.VP1 (135-144) the recombinant AcNS1.FMDV VP1 (135-144) virus was isolated. Similarly from pNS1SpSm.Flu.HA (186-205) the recombinant AcNS1.Flu HA (186-205) virus was isolated.
Detection of chimeric proteins
Expressed chimeric proteins in Sf cells were visualized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie blue staining. For Western blot analyses, resolved proteins from gels were transferred to an immobilon-P membrane (Millipore, Bedford, MA) by standard blotting procedure and probed with either anti-NS1 or anti-FMDV VP1 (p135-160) mouse antiserum for 2 h at 37°C. The membrane was then washed and incubated with an alkaline phosphatase labeled anti-mouse IgG rabbit antiserum (Dakopatts) for 1 h at 37°C and washed three times and the reaction developed by the addition of the substrate NBT/ BCIP.
Purification of tubules
Baculovirus-expressed chimeric mutant BTV-10 NS1 tubules were purified as described previously (Urakawa and Roy, 1988; Monastyrskaya et al., 1995) . Sf-9 cells were infected in suspension culture with recombinant AcNPV viruses using a m.o.i. of 5. After incubation at 28°C for 72 h, cells were harvested, washed with PBS, resuspended in STE buffer (150 mM NaCl, 1 mM EDTA, 10 mM Tris-HCl, pH 7.5) containing 0.5% v/v Triton X-100, and lysed by homogenization. The lysate was clarified by centrifugation (5 min at 3500 rpm) and the supernatant loaded onto a cushion of 3 ml of 40% (w/v) sucrose in STE and centrifuged in a SW41 rotor (2 h at 35,000 rpm). The resulting pellet was resuspended in a small volume of STE and loaded onto a 10-40% gradient of sucrose in STE and centrifuged in a SW28 rotor (1 h at 19,000 rpm). The gradient was fractionated (1.5 ml) and the pellet and each fraction were analyzed by SDS-PAGE for the presence of chimeric NS1.
Electron microscopy
Sucrose gradient purified wild-type and chimeric NS1 tubules in STE buffer were adsorbed onto carbon-coated copper 400-mesh electron microscopy grids for 2-3 min, washed with water, and negatively stained with 2% (w/v) phosphotungstic acid. Grids were examined with a Hitachi H7000 electron microscope at 75 kV. For in situ localization of tubules, cells infected with recombinant baculoviruses expressing either wild-type or chimeric mutant NS1 were fixed in 1% glutaraldehyde and embedded in Epon for sectioning. Sections on grids were then stained with lead citrate and uranyl acetate.
T cell proliferation assays
T cell proliferation assays were performed in triplicate in 200-L volumes in 96-well microtiter plates as described previously by Barnett et al. (1989a,b) . In brief, 2 ϫ 10 4 were incubated with antigen-presenting cells [APC; irradiated (3000 rad) syngeneic spleen cells (4 ϫ 10 5 )] together with chimera, peptide, or medium alone for 72 h for 37°C, pulsed for a further 6 h with [ 3 H]thymidine ( 3 H-TdR; 1 Ci/ml), and acid-perceptible radioactivity determined. The results represent the arithmetic mean of [ 3 H] incorporation for triplicate cultures and were reproducible in three or more independent determinations.
Measurement of IFN-␥
The level of IFN-␥ in culture supernatants was monitored by ELISA using standard protocol. In brief, 96-well plates were coated with 1 g/ml (100 l) anti-IFN-␥ monoclonal antibody diluted in NaCO 3 at pH 8.3 and incubated overnight at 4°C. The wells were then blocked with 200 l 3% bovine serum albumin (BSA) in phosphate-buffered saline (PBS)-Tween for 2 h at room temperature. Conditioned culture media from stimulated clones (100 L) were added to duplicate wells and incubated overnight at 4°C. The wells were washed with PBS-Tween and incubated with 1 g/ml biotinylated anti-IFN-␥ monoclonal antibody diluted in 1% BSA in PBS-Tween for 1 h. After four washes, the wells were incubated for 1 h with HRP-streptavidin diluted in PBS and developed with 1.1 mmol/L 2,2Ј-azino-bis(3-ethylbenz-triazoline-6-sulfonic acid in 0.1 mol/L citrate-phosphate buffer (pH 4.2) containing 0.01% H 2 O 2 . Standard curves were generated using human recombinant forms of IFN-␥). The limits of detection of the ELISA assay were 50 pg/ml.
Analysis of antibody response to NS1 FMDV VP1 (135-144)
BALB/c mice were immunized intraperitoneally (i.p.) on days 0, 15, 30, 45, 60, and 75 with either NS1 tubules expressing VP1 (135-144) or wild-type NS1 tubules (ϳ10 g of protein in incomplete Freund's adjuvant per animal per injection). The antibody response was measured by a direct ELISA using a synthetic peptide p135-160 (which represents the amino acid residues of FMDV VP1 O1C between positions 135-160) or FMDV particles as an antigen . Ninety-six-well Immulon 2 ELISA plates (Dynatech) were coated with 10 g/ml of p135-160 diluted in carbonate buffer pH 9.6 for 12 h at 4°C. Plates were then washed three times with PBS containing 0.025% Tween 20 (PBST) and blocked with 3% horse serum in PBST for 1 h at 37°C (all subsequent steps were performed using this buffer). Then, a fourfold dilution of mouse sera to be tested was added and incubated for 1 h at 37°C. Plates were washed three times with PBST and incubated for 1 h at 37°C with peroxidase-labeled rabbit anti-mouse IgG antibodies (Dakopatts). After three washes, the reaction was developed by addition of O-phenylenediamine-H 2 O 2 in citrate buffer pH 5 and read 10 min later at 490 nm in an MR 500 Microplate Reader (Dynatech). Sera were individually tested in a fourfold dilution series in blocking buffer. Serum titres are expressed as the log of the reciprocal of the highest serum dilution which present optical density (OD) readings above the mean OD readings ϩ 3SD of sera from five animals immunized with wild-type NS1 tubules.
Challenge experiments
Mice were challenged with 10 4 SMLD 50 intraperitoneally of FMDV O1 Campos . Protection was determined by the absence of viremia in the challenged mice at 48 h postinfection. Viremia was tested by intramuscular inoculation of 50 l/mice of a 1/10 dilution of peripheral blood to 5-to 6-day-old litter mice, six mice per blood sample.
